Rottapharm Madaus · Small Molecule · Small Molecule
Oxalyt-C is a small molecule developed by Rottapharm Madaus. It is approved for therapeutic indications.
| Company | Rottapharm Madaus |
| Drug Class | Small Molecule |
| Status | Approved |
Oxalyt-C is developed for 1 unique indication across 1 therapeutic area.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Renal and urinary disorders | Calculus urinary | ✓ Approved |
Ananeva Anastasiia A, Akhmetshina Gulnaz G, Sergeeva Iuliia I, Shagimardanova Elena I EI
Two novel HLA-C alleles, HLA-C*03:690 and HLA-C*06:02:117, were detected during routine next-generation sequencing.
Wu Jiayan J, Li Liguo L, Lai Yingyao Y, Li Jinming J et al.
Excess cholesterol accumulates in colorectal cancer (CRC) and promotes its progression, yet systemic cholesterol-lowering has limited benefits and safety concerns. Here we show that redirecting intestinal cholesterol metabolism through the gut microbiota generates a metabolite, 4-cholesten-3-one (4-C-3), which suppresses CRC growth. A screen of microbial cholesterol metabolites showed that 4-C-3 is depleted in faecal and tumour samples from patients with CRC. 4-C-3 suppresses tumour growth in CRC cell lines, patient-derived organoids and xenografts. Mechanistically, 4-C-3 suppresses two major oncogenic drivers of CRC by inhibiting epidermal growth-factor receptor activation and stabilizing mutant oncogenic KRAS in an inactive state, thereby overcoming KRAS-driven resistance to anti-epidermal growth-factor receptor therapy. As proof of concept, restoring 4-C-3 using either Oscillibacter ruminantium, a natural 4-C-3 producer reduced in CRC, or a non-pathogenic Escherichia coli engineered to convert intestinal cholesterol into 4-C-3, lowered intratumoral cholesterol and induced tumour regression in preclinical models without overt toxicity. These findings uncover a microbiota-cholesterol metabolic pathway that can be harnessed through microbiome engineering to selectively target CRC and overcome therapy resistance.
Jiang Yong Jian YJ, Li Chun Mei CM, Huang Cheng Zhi CZ, Huang Jingtao J
Black phosphorus (BP) holds significant promise as a DNA anchoring platform. However, its application is currently limited by inefficient single-stranded DNA (ssDNA) loading arising from electrostatic repulsion and surface corrugation. Herein, we present a dual-mode biointerface engineering strategy utilizing cytochrome c (Cyt c) to bridge the interface between BP and DNA. Unlike simple electrostatic adsorption, Cyt c enhances loading through a synergistic mechanism combining electrostatic attraction with specific protein-aptamer recognition. This dual-mode approach significantly improved the loading efficiency of a Cy5-modified Cyt c aptamer (Cy5-Cyt c Apt) from 21.7% to 66.5% compared to bare BP. The engineered BP/Cyt c interface facilitated effective static fluorescence quenching, enabling the construction of a proof-of-concept biosensing nanoplatform with enhanced capacity in buffer conditions. Mechanistic investigation using proteins with varying isoelectric points confirmed the critical role of specific recognition in this enhancement. This work establishes a simple, rapid, and effective model for constructing robust BP/DNA nanoplatforms with enhanced analytical performance.
Sharma Pragati P, Choudhary Shubhanjali S, Joshi Sindhuja S, Bose Shubhankar S et al.
A transition-metal-free approach for the one-pot synthesis of benzofuro[3,2-c]pyridines, benzofuro[3,2-b]pyridines, and benzofuro[3,2-c]quinolines has been developed by the reaction of suitably chlorinated pyridine N-oxides and quinoline N-oxides with arynes. A tandem three-step protocol involving the cycloaddition-rearrangement-SNAr cyclization by the reaction of 4-chloropyridine N-oxides with in situ generated aryne intermediates provided benzofuro[3,2-c]pyridines. The Cl substitution at the C-3 position of pyridine N-oxides afforded benzofuro[3,2-b]pyridines. The methodology worked successfully with 2-aryl-4-chloroquinoline N-oxides, affording 2-arylbenzofuro[3,2-c]quinolines. The transition-metal-free strategy comprising a multistep cascade is amenable to a modular synthesis of diversely fused benzofuropyridines and benzofuroquinolines.
Edwards Tara N TN, Chen Chien-Sin CS, Cattley Richard T RT, Mehta Isha I et al.
Cutaneous pain-sensing nociceptive neurons can directly recognize pathogen invasion and modulate the resulting host immune response. Neuronal recognition of C. albicans cell wall components is necessary and sufficient for optimal protective local type-17 immune responses. We now report a parallel neuroimmune pathway in which extracellular ATP (eATP) released from C. albicans and keratinocytes activates nonpeptidergic neurons, including Mas-related G protein-coupled receptor D (Mrgprd)-expressing NP1 neurons, through the P2X3 ATP receptor. Ablation of NP1 neurons or P2rx3 increased C. albicans colony-forming units (CFUs), but the induction of type-17 responses was unaffected. Rather, transcriptomic analysis revealed an alteration in genes and pathways associated with barrier repair. P2rx3-/- mice showed increased wound size and transepidermal water loss associated with a delay in barrier repair following C. albicans infection or abrasion. These data identify a neuroimmune circuit where nonpeptidergic neurons sense epidermal damage or infection through eATP and P2X3, resulting in augmented barrier repair and thus host defense.
Nguyen Xuan Hau XH, Nguyen Xuan Hien XH, Nguyen Nhat Tan NT, Le Van Quang Q
The transoral endoscopic thyroidectomy vestibular approach (TOETVA) eliminates visible scarring but introduces technical challenges for recurrent laryngeal nerve (RLN) preservation. Continuous intraoperative neuromonitoring (C-IONM) provides dynamic assessment of nerve function, potentially reducing injury risk. This study reports the initial Vietnamese experience with C-IONM during TOETVA. Thirty-two patients undergoing TOETVA with C-IONM (NIM Vital system, Medtronic) for benign nodules or differentiated thyroid carcinoma were prospectively enrolled. An Automatic Periodic Stimulation (APS) electrode was placed on the vagus nerve for continuous monitoring. Intraoperative loss of signal (LOS) events were recorded, and all patients underwent postoperative laryngoscopy to assess vocal cord function. C-IONM was successfully established in all 33 nerves at risk. Baseline median amplitude was 645.0 (IQR: 520.0-780.0) µV. Intraoperative LOS events occurred in 3 nerves (9.1%): 2 transient events resolved with maneuver adjustment without postoperative deficit; 1 sustained LOS (3.0%) resulted in temporary vocal cord palsy (full recovery within 3 months). The positive predictive value of sustained LOS for temporary palsy was 100%, and the negative predictive value of stable EMG was 100%. No permanent nerve injuries occurred. C-IONM is feasible during TOETVA and may provide useful real-time functional information to guide surgical decision-making. The two transient loss of signal events successfully reversed through timely surgical adjustments suggest that C-IONM may help prevent nerve injury during this technically demanding approach. Larger comparative studies are needed to confirm these preliminary findings.
+9996 more articles available with a free account
Sign up free to view all articles →